Similar articles for PMID: 32198311

Year	Number of Results
2004	1
2011	1
2012	1
2015	3
2016	8
2017	19
2018	22
2019	27
2020	33
2021	27
2022	13
2023	6
2024	16
2025	0

1

¹⁸F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria.

Ortega C, Schaefferkoetter J, Veit-Haibach P, Anconina R, Berlin A, Perlis N, Metser U. Ortega C, et al. J Nucl Med. 2020 Nov;61(11):1615-1620. doi: 10.2967/jnumed.120.241737. Epub 2020 Mar 20. J Nucl Med. 2020. PMID: 32198311 Free article.

2

Prospective Comparison of PET Imaging with PSMA-Targeted ¹⁸F-DCFPyL Versus Na¹⁸F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.

Rowe SP, Li X, Trock BJ, Werner RA, Frey S, DiGianvittorio M, Bleiler JK, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG. Rowe SP, et al. J Nucl Med. 2020 Feb;61(2):183-188. doi: 10.2967/jnumed.119.227793. Epub 2019 Aug 26. J Nucl Med. 2020. PMID: 31451492 Free PMC article. Clinical Trial.

3

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

4

¹⁸F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy.

Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, Lin F, Adler S, Eclarinal P, McKinney YL, Citrin D, Dahut W, Wood BJ, Krishnasamy V, Chang R, Levy E, Merino M, Pinto P, Eary JF, Choyke PL. Mena E, et al. J Nucl Med. 2020 Jun;61(6):881-889. doi: 10.2967/jnumed.119.234799. Epub 2019 Nov 1. J Nucl Med. 2020. PMID: 31676732 Free PMC article.

5

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on ¹⁸F-DCFPyL PET/CT Imaging.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Werner RA, et al. J Nucl Med. 2018 Dec;59(12):1857-1864. doi: 10.2967/jnumed.118.217588. Epub 2018 Sep 6. J Nucl Med. 2018. PMID: 30190304 Free PMC article.

6

A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.

Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G. Liu W, et al. Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):546-555. doi: 10.1016/j.ijrobp.2019.11.001. Epub 2019 Nov 12. Int J Radiat Oncol Biol Phys. 2020. PMID: 31730876

7

Intraindividual Comparison of ¹⁸F-PSMA-1007 and ¹⁸F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.

Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M. Giesel FL, et al. J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21. J Nucl Med. 2018. PMID: 29269569 Free article. Clinical Trial.

8

A Prospective Study on ¹⁸F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.

Rousseau E, Wilson D, Lacroix-Poisson F, Krauze A, Chi K, Gleave M, McKenzie M, Tyldesley S, Goldenberg SL, Bénard F. Rousseau E, et al. J Nucl Med. 2019 Nov;60(11):1587-1593. doi: 10.2967/jnumed.119.226381. Epub 2019 Apr 12. J Nucl Med. 2019. PMID: 30979820 Free PMC article. Clinical Trial.

9

PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.

Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY. Rowe SP, et al. Mol Imaging Biol. 2016 Jun;18(3):411-9. doi: 10.1007/s11307-016-0957-6. Mol Imaging Biol. 2016. PMID: 27080322 Free PMC article. Clinical Trial.

10

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. Chen Y, et al. Clin Cancer Res. 2011 Dec 15;17(24):7645-53. doi: 10.1158/1078-0432.CCR-11-1357. Epub 2011 Oct 31. Clin Cancer Res. 2011. PMID: 22042970 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 32198311

140 results

Results by year